NCT00000809撤回1 期
A Phase I Trial of the Safety and Immunogenicity of MN rsgp120/HIV-1 With the Adjuvants QS-21 and Alum Compared to MN rsgp120/HIV-1 and QS-21 in Infants Born to HIV-Infected Women
适应症
试验速览
研究概览
简要总结
The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.
研究设计
- 研究类型
- Interventional
- 主要目的
- Prevention
入排标准
- 年龄范围
- 1 Day 至 3 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
1 期
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 YearsHerpes SimplexNCT05989672GlaxoSmithKline50
已完成
1 期
Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in AdultsCOVID-19NCT05228314Clover Biopharmaceuticals AUS Pty Ltd153
Unknown
1 期
Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to PlaceboCOVID-19 VaccineNCT04838080Kocak Farma38
已完成
2 期
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in ChildrenOrthomyxoviridae InfectionsInfluenza A Virus InfectionInfluenzaNCT00491985Sanofi Pasteur, a Sanofi Company240
已完成
1 期
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected AdultsHIV InfectionsNCT04927585Worcester HIV Vaccine42